Helen of Troy (HELE) Q3 2026 earnings review
Acquisition Masks Double-Digit Organic Decay
Helen of Troy's headline revenue decline of 3.4% hides a far more concerning reality: organic business collapsed 10.8%. The 7.1% lift from the Olive & June acquisition is the only thing preventing a double-digit topline drop. Profitability is deteriorating rapidly, with Adjusted EPS falling 36% YoY to $1.71. The company is battling on multiple fronts: intense tariff headwinds compressed gross margins by 200 basis points, and a massive $65.9M asset impairment charge signals continued destruction of shareholder value. While management cites 'stabilization,' the financials show a company using M&A to paper over deep structural weakness in core categories like hair appliances and water filtration.
🐂 Bull Case
The recent acquisition contributed $37.7M in revenue (+7.1% impact), effectively propping up the Beauty & Wellness segment. As the only significant growth engine, its integration is currently the brightest spot in the portfolio.
Despite broader weakness, the Home & Outdoor segment saw strong demand for travel and technical packs (Osprey), suggesting brand equity remains intact in specific lifestyle categories.
🐻 Bear Case
Organic sales plummeted 10.8%, with declines across almost all major categories: insulated beverageware, hair appliances, prestige hair care, thermometers, and humidifiers. The core business is shrinking.
Gross margins fell 200bps to 46.9%, and Adjusted Operating Margin compressed 370bps to 12.9%. Tariffs and 'unfavorable operating leverage' (fixed costs on lower sales) are squeezing profitability faster than revenue is falling.
⚖️ Verdict: 🔴🔴
Strong Sell. The divergence between organic decay (-11%) and the 'stabilization' narrative is alarming. With tariffs crushing margins, debt rising to fund M&A, and persistent asset impairments ($806M YTD), the fundamentals are deteriorating.
Key Themes
Tariffs Crushing Gross Margin
Tariffs are no longer a theoretical risk; they are a realized drag. Consolidated gross profit margin dropped 200 basis points to 46.9%, primarily driven by net unfavorable tariff impacts. Management is attempting to diversify production outside of China (targeting <25-30% China exposure by year-end), but the current financial damage is severe and immediate.
Asset Impairments Signal Value Destruction
The company recorded another $65.9M in pre-tax non-cash asset impairment charges this quarter, bringing the YTD total to a staggering $806.7M. These charges, driven by 'sustained decline in the Company’s stock price,' reflect a fundamental repricing of the business's intangible value and goodwill.
China Market Deterioration
International sales fell 8.1%, driven largely by 'evolving dynamics' in China. Specifically, the company cited a shift away from cross-border ecommerce to localized fulfillment and heightened competition from domestic sellers benefiting from government subsidies. This structural shift threatens the Thermometry and Beauty businesses in the region.
Olive & June Acquisition
The acquisition added $37.7M to the Beauty & Wellness top line in Q3. Without this inorganic boost, the segment would have contracted by nearly 14%. While accretive to revenue, the reliance on M&A to offset core declines increases execution risk and debt load (interest expense up $3.7M YoY).
Operating Leverage Turning Negative
SG&A ratio ballooned 160 basis points to 35.6%. Management cited 'unfavorable operating leverage due to the decrease in net sales' alongside higher freight and incentive comp. The company is unable to cut costs fast enough to match the speed of the organic revenue decline.
Tax Expense Volatility
Income tax expense spiked to $60.0M on a pre-tax *loss* of $24.0M. This anomaly is due to non-deductible impairment charges and valuation allowances on deferred tax assets. This creates a disconnect where the company is bleeding GAAP money but still paying significant cash taxes or recording tax expenses.
Other KPIs
Decelerating. Revenue fell 6.7% YoY. Operating income in this segment was wiped out, recording a loss of $0.1M (GAAP) vs a $40.3M profit a year ago, primarily due to impairment charges and tariff costs.
Decelerating. While reported sales were flat (-0.5%), the organic business is in freefall. Declines were noted in hair appliances, prestige hair care, thermometers, and humidifiers. A 'weak illness season' in Asia was cited as a headwind.
Decelerating. Down from $56.1M in the prior year period. Cash flow is being pressured by $58M in cash outflows related to higher tariff payments, significantly hampering liquidity.
Guidance
Decelerating. The guidance implies a full-year decline of 7.1% to 7.8% vs FY25 ($1.91B). This confirms that the Q3 'stabilization' is relative to a lower baseline, not a return to growth.
Decelerating. Represents a massive contraction from $7.17 in FY25 (approx -50% YoY). The outlook reflects lower gross margins (tariffs), higher incentive comp, and negative operating leverage.
Decelerating. The enormous GAAP loss is driven by the ~$806M in asset impairment charges recognized YTD. This metric highlights the disconnect between adjusted figures and the actual accounting reality of the company's asset values.
Key Questions
Organic Stabilization Timeline
With organic sales down 10.8% and declines across nearly all categories (Beverageware, Beauty, Health), what specific leading indicators give you confidence that the core business will floor in FY27?
Tariff Mitigation vs. Pricing Power
Gross margins compressed 200bps due to tariffs. Given the 'softer consumer demand' mentioned, do you have the pricing power to pass these costs on, or should we expect structural margin compression to persist?
Debt Covenants & Liquidity
The Net Leverage Ratio has risen to 3.77x (vs 2.35x a year ago). With the Credit Agreement Amendment reducing the revolver to $750M and capping leverage at 4.50x, how does this constrain your capital allocation and ability to support the business if EBITDA continues to decline?
Impairment Charge Magnitude
You have taken over $800M in impairment charges YTD. Does this mark the end of the write-downs, or is there still significant goodwill risk on the balance sheet if the stock price remains depressed?